The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies

For more than a week, Boston’s Adult Stem Cell Technology Center, LLC has been declining offers from participants in the Amyotrophic Lateral Sclerosis (ALS) Ice Bucket Challenge who wish to make donations for research that does not use human embryonic stem cells or tissues derived from aborted fetuses. The company has informed those wishing to donate that its for-profit status prevents it from inviting or receiving charitable donations.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

James L. Sherley, M.D., Ph.D., Director of ASCTC

The best thing about this unfortunate situation is that I have had the pleasure of communicating with some very caring people…and that is quite inspiring!

Boston, MA (PRWEB) August 29, 2014

Due to a misstatement posted by the Family Resource Council (FRC) last week, the Adult Stem Cell Technology Center, LLC (ASCTC) was reported as an entity accepting donations to support stem cell therapy research that might benefit ALS patients. Because of ASCTC's exclusive focus on developing adult stem cells for new stem cell technologies and therapeutic applications, FRC listed ASCTC as one of several alternatives for ALS Ice Bucket Challenge donors who wish not to support research that requires the death of human embryos or fetal abortions.

After authorizing the listing by FRC, ASCTC's Director James Sherley states that he was surprised by suddenly receiving a number of communications from individuals inquiring how to donate to ASCTC. A look at the FRC posting explained the contacts. Inadvertently, ASCTC had been indicated as an agency that received donations for stem cell research. After ASCTC notified FRC staff of the mistake, the posting was immediately corrected. Since the correction, Director Sherley reports that the number of donation contacts has decreased, but not stopped completely.

In addition to the FRC correction, the ASCTC now responds to donation inquiries with the following statement:

“Thank you for your interest in donating to ASCTC to support its development efforts in adult stem cell technologies. If your query was motivated by a recent Family Resource Council (FRC) notice, unfortunately, the notice posted by FRC was mistaken in its 'donate' message and did not adequately indicate that ASCTC is a for-profit company. Therefore, there is no means by which to 'donate' to the company.
     At my request, FRC has now corrected the posting. It is possible to invest in ASCTC commercial development of technologies for producing and quantifying human adult stem cells for drug development and therapeutics. However, this was not the intent of the FRC notice. Its purpose was to make the public aware of all the entities, not-for-profit or for-profit, engaged in developing stem cell technologies, potentially relevant to finding a cure for ALS, that do not use human embryonic stem cells.
     Please, accept my apologies for the miscommunication; and thank you for your good will in supporting ethical research to help others suffering from devastating illnesses like ALS.

Sincerely,

James L. Sherley
Director
ASCTC, LLC”

Director Sherley observed, “The best thing about this unfortunate situation is that I have had the pleasure of communicating with some very caring people…and that is quite inspiring!”
*************************************************************************************************************
The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.


Contact